Orexo in brief

Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales for 2022 amounted to SEK 624 million and the number of employees was 126.

  • Developed four commercial pharmaceutical products with worldwide approval
  • Addresses unmet need within the growing space of mental illness and addiction disorders
  • Broad product portfolio and development pipeline of pharma products and digital mental health programs
  • Strategic focus on portfolio expansion through development, licensing and M&A
  • Strong cash generation from the business area US Pharma enabling to invest in future growth.

Orexo’s business model is integrated and includes the entire value chain, from the innovation phase to product access and commercialization. Cross-functional teams bring together specialist competencies to evaluate new development projects funded by revenues from the company’s own sales or out-licensing of products and development projects.

 Discover our story 

Own commercial plattform in the US

Own commercial plattform in the US

Since 2013, Orexo has been commercializing its key product ZUBSOLV®, for treatment of opioid dependence, in the US. The company's own sales force covers large parts of the country and in 2020 an important milestone was reached when ZUBSOLV´S total gross sales, since start, exceeded USD 1 billion.

The new future starts to take shape

The new future starts to take shape

One of the most important objectives has been to broaden the product portfolio to capitalize the US commercial organization. In 2019, a collaboration was initiated with GAIA, a world leader in the development of digital therapeutics, and in 2020, Orexo's product portfolio grew with three digital therapies.